Zhengbin Yao
President and CEO at ArriVent BioPharma Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2024
5 years of board service in total across 2 boards, counting each seat separately. Longest: ArriVent BioPharma Inc., 2 years.
ArriVent BioPharma Inc.
Director · President and CEO
Alumis Inc.
Director
Chief executive roles
ArriVent BioPharma Inc.
· President and CEO
Since January 2024
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | Alumis Inc. | Grant or award | +3,553 | — | — |
| Jul 1, 2024 | Alumis Inc. | Sold back to the company | −23,529 | — | — |
| Jul 1, 2024 | Alumis Inc. | Grant or award | +23,529 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.